Dr Kathryn Aston-Mourney

Cytokine-inducible SH2 domain containing protein contributes to regulation of adiposity, food intake, and glucose metabolism

W Naser, S Maymand, L Rivera, T Connor, C Liongue, C Smith, K Aston-Mourney, D McCulloch, S McGee, A Ward

(2022), Vol. 36, FASEB Journal, C1

Clinical features, complications and treatment of rarer forms of maturity-onset diabetes of the young (MODY) - a review

R Aarthy, K Aston-Mourney, A Mikocka-Walus, V Radha, A Amutha, R Anjana, R Unnikrishnan, V Mohan

(2021), Vol. 35, pp. 1-27, Journal of diabetes and its complications, Amsterdam, The Netherlands, C1

Quality of Life and Diabetes in India: A scoping review

R Aarthy, A Mikocka-Walus, R Pradeepa, R Anjana, V Mohan, K Aston-Mourney

(2021), Vol. 25, pp. 365-380, Indian Journal of Endocrinology and Metabolism, Mumbai, India, C1

Copper ionophores as novel antiobesity therapeutics

P Meggyesy, S Masaldan, S Clatworthy, I Volitakis, D Eyckens, K Aston-Mourney, M Cater

(2020), Vol. 25, pp. 1-15, Molecules, Basel, Switzerland, C1

Class IIa HDACs do not influence beta-cell function under normal or high glucose conditions

Jacob McCann, Megan Ellis, Sean McGee, Kathryn Aston-Mourney

(2019), Vol. 11, pp. 112-118, Islets, Abingdon, Eng., C1

Metformin, beta-cell development, and novel processes following beta-cell ablation in zebrafish

G Wyett, Y Gibert, M Ellis, H Castillo, J Kaslin, K Aston-Mourney

(2018), Vol. 59, pp. 419-425, Endocrine, Totowa, N.J., C1-1

APP deficiency results in resistance to obesity but impairs glucose tolerance upon high fat feeding

J Czeczor, A Genders, K Aston-Mourney, T Connor, L Hall, K Hasebe, M Ellis, K De Jong, D Henstridge, P Meikle, M Febbraio, K Walder, S McGee

(2018), Vol. 237, pp. 311-322, Journal of endocrinology, Bradley Stok, Eng., C1

Gene expression signature: a powerful approach for drug discovery in diabetes

S Sithara, T Crowley, K Walder, K Aston-Mourney

(2017), Vol. 232, pp. R131-R139, Journal of endocrinology, Bristol, Eng., C1

Scriptaid enhances skeletal muscle insulin action and cardiac function in obese mice

V Gaur, T Connor, K Venardos, D Henstridge, S Martin, C Swinton, S Morrison, K Aston-Mourney, S Gehrig, R van Ewijk, G Lynch, M Febbraio, G Steinberg, M Hargreaves, K Walder, S McGee

(2017), Vol. 19, pp. 936-943, Diabetes, obesity and metabolism, Chichester, Eng., C1

Pathways of acetyl-CoA metabolism involved in the reversal of palmitate-induced glucose production by metformin and salicylate

B Hayward, J Molero, K Windmill, A Sanigorski, J Weir, N McRae, K Aston-Mourney, B Osborne, B Liao, K Walder, P Meikle, N Konstantopoulos, C Schmitz-Peiffer

(2016), Vol. 124, pp. 602-612, Experimental and clinical endocrinology and diabetes, Munich, Germany, C1

One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice

K Aston-Mourney, S Subramanian, S Zraika, T Samarasekera, D Meier, L Goldstein, R Hull

(2013), Vol. 305, American Journal of Physiology: Endocrinology and Metabolism, Bethesda, MD, C1

Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis

M Smits, P Woudstra, K Utzschneider, J Tong, F Gerchman, M Faulenbach, D Carr, K Aston-Mourney, A Chait, R Knopp, J Meigs, E Boyko, S Kahn

(2013), Vol. 23, pp. 415-421, Annals of Epidemiology, Amsterdam, Netherlands, C1-1

Rosiglitazone Treatment Does Not Decrease Amyloid Deposition in Transplanted Islets From Transgenic Mice Expressing Human Islet Amyloid Polypeptide

J Udayassankar, S Zraika, K Aston-Mourney, S Subramanian, B Brooks-Worrell, G Taborsky, R Hull

(2013), Vol. 45, pp. 574-579, Transplantation Proceedings, New York, NY, C1-1

Matrix Metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide

K Aston-Mourney, S Zraika, J Udayasankar, S Subramanian, P Green, S Kahn, R Hull

(2013), Vol. 288, pp. 3553-3559, The journal of biological chemistry, Bethesda, Maryland, C1

cJUN N-terminal kinase (JNK) activation mediates islet amyloid-induced beta cell apoptosis in cultured human islet amyloid polypeptide transgenic mouse islets

S Subramanian, R Hull, S Zraika, K Aston-Mourney, J Udayasankar, S Kahn

(2012), Vol. 55, pp. 166-174, Diabetologia, Heidelberg , Germany, C1-1

B-cell loss and B-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition

C Jurgens, M Toukatly, C Fligner, J Udayasankar, S Subramanian, S Zraika, K Aston-Mourney, D Carr, P Westermark, G Westermark, S Kahn, R Hull

(2011), Vol. 178, pp. 2632-2640, American journal of clinical pathology, Birmingham, Ala., C1-1

Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets

K Aston-Mourney, R Hull, S Zraika, J Udayasankar, S Subramanian, S Kahn

(2011), Vol. 54, pp. 1756-1765, Diabetologia, Heidelberg, Germany, C1-1

Neprilysin impedes islet amyloid formation by inhibition of fibril formation rather than peptide degradation

S Zraika, K Aston-Mourney, P Marek, R Hull, P Green, J Udayasankar, S Subramanian, D Raleigh, S Kahn

(2010), Vol. 285, pp. 18177-18183, Journal of biological chemistry, Bethesda, Md., C1-1

Amyloid formation results in recurrence of hyperglycaemia following transplantation of human IAPP transgenic mouse islets

J Udayasankar, K Kodama, R Hull, S Zraika, K Aston-Mourney, S Subramanian, J Tong, M Faulenbach, J Vidal, S Kahn

(2009), Vol. 52, pp. 145-153, Diabetologia, Heidelberg, Germany, C1-1

Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis

S Zraika, R Hull, J Udayasankar, K Aston-Mourney, S Subramanian, R Kisilevsky, W Szarek, S Kahn

(2009), Vol. 52, pp. 626-635, Diabetologia, Heidelberg, Germany, C1-1

Amyloid formation in human IAPP transgenic mouse islets and pancreas, and human pancreas, is not associated with endoplasmic reticulum stress

R Hull, S Zraika, J Udayasankar, K Aston-Mourney, S Subramanian, S Kahn

(2009), Vol. 52, pp. 1102-1111, Diabetologia, Heidelberg, Germany, C1-1

Fructose-1,6-Bisphosphatase overexpression in pancreatic [beta]-cells results in reduced insulin secretion : a new mechanism for fat-induced impairment of [beta]-cell function

M Kebede, J Favaloro, J Gunton, D Laybutt, M Shaw, N Wong, B Fam, K Aston-Mourney, C Rantzau, A Zulli, J Proietto, S Andrikopoulos

(2008), Vol. 57, pp. 1887-1895, Diabetes, Alexandria, Va, C1-1

Too much of a good thing : why it is bad to stimulate the beta cell to secrete insulin

K Aston-Mourney, J Proietto, G Morahan, S Andrikopoulos

(2008), Vol. 51, pp. 540-545, Diabetologia, Heidelberg, Germany, C1-1

Increased nicotinamide nucleotide transhydrogenase levels predispose to insulin hypersecretion in a mouse strain susceptible to diabetes

K Aston-Mourney, N Wong, M Kebede, S Zraika, L Balmer, J McMahon, B Fam, J Favaloro, J Proietto, G Morahan, S Andrikopoulos

(2007), Vol. 50, pp. 2476-2485, Diabetologia, Heidelberg, Germany, C1-1

The influence of genetic background on the induction of oxidative stress and impaired insulin secretion in mouse islets

S Zraika, K Aston-Mourney, D Laybutt, M Kebede, M Dunlop, J Proietto, S Andrikopoulos

(2006), Vol. 49, pp. 1254-1263, Diabetologia, Heidelberg, Germany, C1-1

Investigational agents that protect pancreatic islet β-cells from failure

K Aston-Mourney, J Proietto, S Andrikopoulos

(2005), Vol. 14, pp. 1241-1250, Expert opinion on investigational drugs, England, London, C1-1

Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a high fat diet

S Andrikopoulos, C Massa, K Aston-Mourney, A Funkat, B Fam, R Hull, S Kahn, J Proietto

(2005), Vol. 187, pp. 45-53, Journal of endocrinology, Bristol, England, C1-1

High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction

S Kooptiwut, M Kebede, S Zraika, S Visinoni, K Aston-Mourney, J Favaloro, C Tikellis, M Thomas, J Forbes, M Cooper, M Dunlop, J Proietto, S Andrikopoulos

(2005), Vol. 35, pp. 39-48, Journal of molecular endocrinology, Bristol, England, C1-1